Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time

Details

• Alternative Title:
  Int J Cancer
• Personal Author:
  Zhou, Mi ; Bracci, Paige M. ; McCoy, Lucie S. ; Hsuang, George ; Wiemels, Joseph L. ; Rice, Terri ; Zheng, Shichun ; Kelsey, Karl T. ; Wrensch, Margaret R. ; Wiencke, John K.
• Description:
  Defects in antigen presenting cell function have been implicated in glioma immunosuppression. We measured peripheral CCL22, a dendritic cell/macrophage derived T cell trafficking chemokine, in sera from 1,208 glioma cases and 976 controls to assess whether it might provide a biomarker of glioma risk, survival and immune dysfunction. Cluster models were used to examine the relationship between CCL22 and glioma risk. Patient survival was assessed using Cox regression models. We also examined the relationship between CCL22 levels and CD4 cell counts, as well as allergy history and IgE levels. CCL22 levels were significantly lower among glioma cases compared with controls (Mean ± SEM: 1.23 ± 0.03 ng/mL in cases vs. 1.60 ± 0.03 ng/mL in controls, p < 0.0001) and this difference remained significant even after controlling for other covariates in the cluster models (highest quartile versus lowest Odds Ratio = 0.21, p < 0.0001). CD4 cell counts were positively correlated with CCL22 in glioma cases (Spearman r(2) = 0.51, p < 0.01) and were significantly lower in cases compared with controls. Higher CCL22 levels were associated with longer survival in all cases combined and in GBM cases (hazard ratio(allcases) = 0.81; 95% CI: 0.72-0.91, p = 0.0003). CCL22 levels were not associated with IgE level or self-reported allergies. Circulating CCL22 levels are related to both glioma risk and survival duration independent of age, histology, grade and IDH mutation status. CCL22 should be considered a marker of immune status with potential prognostic value.
• Subjects:
  Aged Antigen-Presenting Cells Biomarkers, Tumor Brain Neoplasms CD4-Positive T-Lymphocytes Chemokine CCL22 Dendritic Cells Female Glioma Humans Immunosuppression Therapy Isocitrate Dehydrogenase Kaplan-Meier Estimate Macrophages Male Middle Aged Prognosis Proportional Hazards Models Risk Factors

  More +
• Keywords:
  CCL22 Cytokines Glioblastoma Survival T Cells
• Source:
  Int J Cancer. 137(4):826-836
• Pubmed ID:
  25604093
• Pubmed Central ID:
  PMC4478165
• Document Type:
  Journal Article
• Funding:
  R01 CA139020/CA/NCI NIH HHSUnited States/ ; R01CA126831/CA/NCI NIH HHSUnited States/ ; U58DP003862-01/DP/NCCDPHP CDC HHSUnited States/ ; HHSN261201000140C/CA/NCI NIH HHSUnited States/ ; HHSN261201000035C/CA/NCI NIH HHSUnited States/ ; R25 CA112355/CA/NCI NIH HHSUnited States/ ; R01 CA126831/CA/NCI NIH HHSUnited States/ ; UL1 RR024131/RR/NCRR NIH HHSUnited States/ ; P50 CA097257/CA/NCI NIH HHSUnited States/ ; U58 DP003862/DP/NCCDPHP CDC HHSUnited States/ ; R01 CA052689/CA/NCI NIH HHSUnited States/ ; R25CA112355/CA/NCI NIH HHSUnited States/ ; HHSN261201000035I/CA/NCI NIH HHSUnited States/ ; P50CA097257/CA/NCI NIH HHSUnited States/ ; HHSN261201000034C/CA/NCI NIH HHSUnited States/ ; R01CA139020/CA/NCI NIH HHSUnited States/ ; R01CA52689/CA/NCI NIH HHSUnited States/
• Volume:
  137
• Issue:
  4
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:a1dca27876ee2cf8daf6d4790faa19fcca8c661e080137c3345ab42b84bce434
• Download URL:
  https://stacks.cdc.gov/view/cdc/32967/cdc_32967_DS1.pdf
• File Type:
  [PDF - 873.49 KB ]